Latest Content

The patient was a rare case of a patient with dedifferentiated liposarcoma and a high tumor mutational burden.

Top articles in 2025 covered advancements in acute myeloid leukemia treatments, including allogeneic CAR T-cell therapy.

Eunice Wang, MD, highlights breakthroughs in menin inhibitors for acute leukemias, showcasing promising combination therapies and addressing treatment challenges at ASH 2025.

New research reveals teclistamab and daratumumab significantly enhance progression-free survival in multiple myeloma, reshaping treatment standards.

Lerodalcibep-liga subcutaneous injection is now approved for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.

Developers say more accurate automated multiple sclerosis lesion segmentation can improve research and patient care.

Two-thirds of pharmaceutical companies did not proactively release the launch price of their medications from 2022 to 2024.

Recent political shifts impacting health policy and access to care for millions dominated the news in 2025.

Blinatumomab enhances survival in pediatric B-cell ALL, yet homecare challenges hinder its outpatient delivery.